找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Lung Cancer; Treatment and Resear Karen L. Reckamp Book 2016 Springer International Publishing Switzerland 2016 Genomics.Lung cancer.Lung n

[复制链接]
楼主: Jackson
发表于 2025-3-26 22:21:11 | 显示全部楼层
Chemotherapy for Advanced Non-small Cell Lung Cancer,cular drivers and the role of the immune system in cancer therapy have brought new drugs to the armamentarium. Despite these advances, cytotoxic chemotherapy remains a substantial part of therapy for most patients in locally advanced and metastatic stage. Initially thought to be a chemotherapy-resis
发表于 2025-3-27 03:19:28 | 显示全部楼层
Multimodality Therapy for NSCLC, Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains unclear. Targeted therapy has met limited success in the treatment of unselected patients with stage I
发表于 2025-3-27 07:36:17 | 显示全部楼层
发表于 2025-3-27 10:03:27 | 显示全部楼层
Immunotherapy in Lung Cancer,vital to malignant progression. Immunotherapies act by enhancing the patient’s innate immune response and hold promise for inducing long-term responses in select patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Immune checkpoint inhibitors, in particular, inhibitor
发表于 2025-3-27 16:01:39 | 显示全部楼层
Palliative Care in Lung Cancer, with advanced lung cancer is very high and has a negative impact on their quality of life (QOL). Palliative care with its focus on the management of symptoms and addressing physical, psychosocial, spiritual, and existential suffering, as well as medically appropriate goal setting and open communica
发表于 2025-3-27 20:41:48 | 显示全部楼层
Management of Lung Cancer in the Elderly,e-half of patients with lung cancer fall into the elderly subgroup. There is dearth of high level of evidence regarding the management of lung cancer in the elderly in the three broad stages of the disease including early-stage, locally advanced, and metastatic disease. A major reason for the lack o
发表于 2025-3-28 01:22:15 | 显示全部楼层
发表于 2025-3-28 03:44:44 | 显示全部楼层
Small Cell Lung Cancer,y present with a short duration of symptoms and frequently (60–65 %) with metastatic disease. SCLC is a heterogeneous disease including extremely chemosensitive and chemoresistant clones. For this reason, a high percentage of patients respond to first-line chemotherapy but rapidly succumb to the dis
发表于 2025-3-28 08:33:31 | 显示全部楼层
发表于 2025-3-28 11:12:19 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-7 13:37
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表